Southampton based research firm, Synairgen, has rocketed in morning trading after announcing results for a treatment which could protect asthmatics from respiratory virus infections.
The drug, called SNG001, stops infections like the common cold spreading to patients' lungs, which is often the cause of hospital admissions for asthma sufferers.
The study investigated SNG001 in a population of 134 adult asthma patients, representing 'mild-moderate' through to 'severe' asthmatics, who caught a cold.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Patients with 'difficult to treat' asthma, being approximately half of the patients in the trial, benefitted significantly from SNG001 treatment. This category of patient is estimated to represent between 10% and 20% of all adult asthma sufferers.
Professor Stephen Holgate, the founder of Synairgen, said: "This is the first clinical study which appears to demonstrate that, by boosting the antiviral defences of the lungs of asthmatics...we can...prevent worsening of asthma symptoms in a high risk group of patients."
He'll certainly have been breathing easily after looking at his firm's share price this morning, the stock had gained 27.6% by 10:59.
BS
-
Trouble brews in B&M as bargain shops take a hitOpinion Once a stock market darling, B&M's share price has slumped. What has gone wrong for bargain shops?
-
US and China reach a ceasefire in their trade war after talks in LondonThe US and China's trading relationship – the most important one in the global economy – is back on track. Will the truce last?
